title: Outpatient intravenous treatment for infective endocarditis: safety, effectiveness and one-year outcomes.
abstract: OBJECTIVE
  To describe the use and outcomes of outpatient antimicrobial therapy (OPAT) for infective endocarditis (IE) within the Canterbury region of New Zealand over an 8 year period.
  
  
  METHODS
  All cases of IE admitted to Christchurch Hospital were reviewed. Prospectively collected data from our OPAT service's database and retrospective data from case notes were analysed.
  
  
  RESULTS
  There were 213 episodes of IE meeting modified Duke Criteria over this time. Patients received OPAT in 100 episodes. Viridans streptococci were the infecting organism in 34, Staphylococcus aureus in 27, and enterococci in 10. Adverse events were encountered in 27 episodes. Of these, 24 were related to intravenous lines, infusion devices or adverse drug reactions which resolved with change of treatment. There were 3 serious adverse events which were likely to have occurred in hospital. During 12-month follow-up there were 5 further episodes of IE and 2 deaths unlikely to be directly related to the episode of IE.
  
  
  CONCLUSIONS
  Despite significant co-morbidities and complications, nearly half of all patients with IE, including those with disease due to S. aureus and enterococci, successfully completed their treatment as outpatients. Continuous infusion devices were successfully used in 32 patients, including 22 with disease due to S. aureus.
authors.affiliation: Department of Microbiology, Canterbury Health Laboratories, Corner Hagley Ave & Tuam Street, Christchurch 8011, New Zealand. matthew.amodeo@cdhb.govt.nz
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Amodeo
authors.forename: Tamlin
authors.initials: T
authors.lastname: Clulow
authors.forename: John
authors.initials: J
authors.lastname: Lainchbury
authors.forename: David R
authors.initials: DR
authors.lastname: Murdoch
authors.forename: Kate
authors.initials: K
authors.lastname: Gallagher
authors.forename: Amanda
authors.initials: A
authors.lastname: Dyer
authors.forename: Sarah L
authors.initials: SL
authors.lastname: Metcalf
authors.forename: Alan D
authors.initials: AD
authors.lastname: Pithie
authors.forename: Stephen T
authors.initials: ST
authors.lastname: Chambers
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D007260:Infusion Pumps; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009520:New Zealand; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents